United Healthcare and OneOncology have added Amgen’s MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns), biosimilars to AVASTIN and HERCEPTIN respectively, as preferred products, according to literature released by those providers.
United Healthcare released a bulletin indicating that, as of October 1, 2019, United Healthcare will update its preferred product language to reflect the “use of Mvasi (bevacizumab-awwb) prior to the use of Avastin and other bevacizumab biosimilar products” and the “use of Kanjinti (trastuzumab-anns) prior to the use of Herceptin and other trastuzumab biosimilar products.” Additionally, the bulletin indicates that, on October 1, United Healthcare’s preferred product language will be updated to include “use of Zarxio® [Sandoz’s biosimilar filgrastim] prior to the use of Granix®, Neupogen® and Nivestym.” Furthermore, the Center for Biosimilars reports that United Healthcare intends to add INFLECTRA (Pfizer’s biosimilar infliximab) to a preferred position along with REMICADE as of October 1 as well.
OneOncology has also stated in a press release that its partner practices have already begun administering MVASI and KANJITI to patients as “preferred formulary agents”. According to the press release, the adoption of the biosimilars has resulted in an estimated 15% cost savings.
The post United Healthcare and OneOncology Update Preferred Products to Include Biosimilars appeared first on Big Molecule Watch.